Home

AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

AstraZeneca has announced the launch of the 2023 R&D Postdoctoral Challenge, an initiative designed to accelerate ideas to transform the treatment of some of the world’s most complex diseases.

The R&D Postdoctoral Challenge has been designed to drive R&D productivity, promote diversity of thought and stimulate research opportunities across the globe.

DNA treatment could delay paralysis that strikes nearly all patients with ALS

In virtually all persons with amyotrophic lateral sclerosis (ALS) and in up to half of all cases of Alzheimer's disease (AD) and frontotemporal dementia, a protein called TDP-43 is lost from its normal location in the nucleus of the cell. In turn, this triggers the loss of stathmin-2, a protein crucial to regeneration of neurons and the maintenance of their connections to muscle fibers, essential to contraction and movement.

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of $43 billion.

First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the drug Foralumab, an anti-CD3 monoclonal antibody. Investigators found evidence that the drug dampened the inflammatory T cell response and decreased lung inflammation in patients with COVID-19.

Digital twin opens way to effective treatment of inflammatory diseases

Inflammatory diseases like rheumatoid arthritis have complex disease mechanisms that can differ from patient to patient with the same diagnosis. This means that currently available drugs have little effect on many patients. Using so-called digital twins, researchers at Karolinska Institutet have now obtained a deeper understanding of the "off and on" proteins that control these diseases.

AI conjures proteins that speed up chemical reactions

For the first time, scientists have used machine learning to create brand-new enzymes, which are proteins that accelerate chemical reactions. This is an important step in the field of protein design as new enzymes could have many uses across medicine and industrial manufacturing.

Pill for skin disease also curbs excessive drinking

Researchers from Oregon Health & Science University and institutions across the country have identified a pill used to treat a common skin disease as an "incredibly promising" treatment for alcohol use disorder.

The study was recently published in the Journal of Clinical Investigation.

PharmaNews.eu

AstraZeneca launches call for entries to the 2023 global R&D Postdoctoral Challenge

DNA treatment could delay paralysis that strikes nearly all patients with ALS

Pfizer invests $43 billion to battle cancer

First nasal monoclonal antibody treatment for COVID-19 shows promise for treating virus, other diseases

Digital twin opens way to effective treatment of inflammatory diseases

AI conjures proteins that speed up chemical reactions

Pill for skin disease also curbs excessive drinking

More Pharma News ...